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1ABSTRACT
Anti-tumor activity and acquired resistance mechanism of Dovitinib 
(TKI258) in RET rearranged lung adenocarcinoma
Chan Woo Kang
Department of Medical Science
The Graduate School, Yonsei University
(Directed by Professor Byoung Chul Cho)
RET rearrangement is a newly identified oncogenic mutation in lung 
adenocarcinoma (LADC). Activity of dovitinib (TKI258), a potent inhibitor of 
FGFR, VEGFR, and PDGFR, on RET-rearranged LADC has not been known. The 
aims of the study are to explore antitumor effects and mechanism of acquired 
resistance of dovitinib in RET-rearranged LADC. In silico analysis results indicated 
that dovitinib strongly interacts with the surrounding residues in RET kinase 
domain, dovitinib potently induced cell cycle arrest in G1 phase and does-
dependent suppression of phosphorylation of RET and ERK in LC-2/ad LADC cells 
harboring CCDC6-RET rearrangement. The therapeutic effects of dovitinib were 
photocopied by siRNA knockdown of RET. Selective inhibition of dovitinib on 
autophosphorylation of RET kinases was confirmed in HEK293 cells expressing 
2KIF5B-RET or CCDC6-RET. A phospho-RTK array reveals that LC-2/ad cells 
maintain phosphorylation of FGFRs and VEGFRs in the presence of dovitinib. 
Dovitinib inhibited ERK phosphorylation more efficiently than vandetanib, 
sunitinib and sorafenib. The effects on ERK phosphorylation were correlated with 
the results of cell viability assays. Antitumor effect of dovitinib was observed in 
tumor xenograft model. To identify the acquired resistance mechanism, dovitinib-
resistant cells (LC-2/ad DR) were established by exposure of LC-2/ad to stepwise 
increasing concentration of dovitinib. Knockdown of RET or dovitinib treatment 
did not inhibit ERK phosphorylation in LC-2/ad DR cells. Saracatinib, a src kinase 
inhibitor, suppressed ERK phosphorylation and growth of LC-2/ad DR cells. Taken 
together, dovitinib can be a potential therapeutic option for RET-rearranged LADC, 
and acquired resistance to dovitinib can be overcome by targeting SRC.
Key Words: lung adenocarcinoma, non-small cell lung cancer, RET rearrangement,
dovitinib (TKI258), Src, acquired resistance
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I. INTRODUCTION
Lung cancer is the most common cause of cancer death worldwide.1 Although 
survival of lung cancer patients still remains poor, molecular targeted therapies, 
which block important oncogenic pathways, have made remarkable progress over 
the years, particularly in lung adenocarcinoma (LADC), which is the most common 
histological subtype of lung cancer.2-4 Indeed, treatment with gefitinib or crizotinib
in EGFR mutation-positive or ALK-rearranged advanced LADC, respectively, has 
led to unprecedented improvements in objective response rate and progression-free 
survival over cytotoxic chemotherapy.5 The prevailing concept of genomics-driven 
medicine based on remarkable efficacy of these targeted therapies and the 
expanding genomic landscape of LADC have led to a significant surge in the 
4number of genotype-directed lung cancer trials in molecular subtypes defined by 
oncogenic driver mutations in PIK3CA, HER2, BRAF, and ROS1. 1
RET encodes the tyrosine kinase receptor of growth factors belonging to the 
glial-derived neurotrophic factor family. Recently, RET rearrangement, specifically 
fusion, has emerged as a new molecular subtype in LADC.6, 7 The prevalence of 
RET fusions has been estimated as approximately 1.2% to 2.0% in LADC.6-11
Several RET fusions have been identified in LADC, including kinesin family 
member 5B (KIF5B)-RET, coiled-coil domain containing 6 (CCDC6)-RET, 
tripartite motif-containing 33 (TRIM33)-RET and nuclear receptor coactivator 4 
(NCOA4)-RET. Among all fusion variants, KIF5B-RET is the most common type of 
fusion involving RET, present in approximately 90% of cases reported to date.9  
RET fusion was mutually exclusive with other oncogenic driver mutations, such as 
EGFR, HER2, BRAF or EML4-ALK fusion.9, 10, 12, 13 Furthermore, expression of 
exogenous KIF5B-RET induced morphological transformation and anchorage-
independent growth of NIH3T3 fibroblasts. 7 These findings strongly suggest that 
targeted inhibition of RET oncogene might be a potential strategy in the treatment of 
RET fusion-positive LADC. 
Small molecule tyrosine kinase inhibitors (TKIs), including vandetanib, 
sunitinib and sorafenib, effectively inhibited RET fusion-positive LADC in 
preclinical models.7, 10, 11, 14, 15 Therefore, several clinical trials of RET inhibitors are 
ongoing in RET fusion-positive LADC. Recently, treatment of cabozantinib and 
5vandetanib, which have RET inhibitory activity, resulted in dramatic responses in 
patients with RET fusion-positive LADC.12, 16
Dovitinib (TKI258) is a potent inhibitor of receptor tyrosine kinases, including 
fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor 
(VEGFR) 1-3, platelet derived growth factor receptor (PDGFR)-β, which has shown 
anti-tumor and anti-angiogenic effects in preclinical models of colon, breast, 
bladder, pancreatic, and renal cell cancers.17-19 However, anti-tumor activity of 
dovitinib in RET-rearranged LADC has not been reported, except for the fact that 
dovitinib inhibits the RET kinase at a range of 7nM in in vitro kinase assay (Ref: 
dovitinib investigator’s brochure). 
Herein, we show potent anti-tumor activity of dovitinib in preclinical models 
of RET-rearranged LADC. Additionally, we report the mechanism of acquired 
resistance to dovitinib in RET-rearranged LADC. 
6II. MATERIALS AND METHODS
1. Compounds, antibodies, and cell lines
Dovitinib was kindly provided by Novartis Institutes for Biomedical Research 
(Basel, Switzerland). Gefitinib, vandetanib, sorafenib, sunitinib and saracatinib 
were purchased from Selleck Chemical. Antibodies against EGFR, p-EGFR, RET, 
p-RET (Y905), AKT, p-AKT (S473), ERK1/2, p-ERK1/2 (T202/Y204), Cyclin D1, 
p21, p27, FAK, p-FAK (Y397), Src, p-Src (Y416), Paxillin, p-Paxillin (Y118) and 
Integrin β1, were purchased from Cell Signaling Technology. Rabbit polyclonal   
antibody to RET (p-Y1062) (ab51103) was purchased from Abcam. Anti-β-actin 
antibody was purchased from Sigma Aldrich. LC-2/ad cells, a human LADC cell 
line harboring CCDC6-RET fusion, were purchased from RIKEN. H1299 cells and 
HEK293 cells were purchased from American Type Culture Collection. Each cell 
line was cultured using the medium recommended by the suppliers.
2. Plasmid constructs and transfection
The plasmids that express KIF5B-RET, CCDC6-RET, and KRAS G12V were 
purchased from Addgene. HEK293 cells were plated at a density of 0.5 × 105 per 60 
mm dish 1 day before transfection. HEK293 cells were transfected with the 
appropriate expression plasmids using Polyjet transfection reagent (SignaGenat), 
according to the manufacturer’s instructions. Transfected HEK293 cells were 
cultured at 37 °C for 24 hr and then treated with or without dovitinib for an 
7additional 4 hr prior to lysis. 
3. Growth inhibition assay
For MTT assays, cultured cells were seeded into 96-well plates (3,000 cells per 
well). Twenty-four hours after seeding, serial dilutions of appropriate inhibitors 
were added to the culture. After 72 hr, 50 µl of MTT (5 mg/ml stock solution) was 
added and the plates were incubated for an additional 4 hr. The medium was 
discarded and the formazan blue, which was formed in the cells, was dissolved with 
100 µl DMSO. The optical density was measured at 540 nm. Relative survival in 
the presence of drugs was normalized to DMSO control cells after background 
subtraction. For colony formation assays, cells were seeded into 6-well plates (2.5 x 
104 cells per well) and treated with the agents indicated. RMPI-1640 containing 10% 
FBS for 14 days. Compound treatments were replaced at least every 3 days during 
the assay. After 14 days, cells were fixed in 3% paraformaldehyde in phosphate 
buffered saline (PBS) for 10 min at room temperature and stained with 0.5% crystal 
violet in 20% methanol for 20 min. Images were captured using flatbed scanner, and 
the cells were dissolved with 20% acetic acids in 20% methanol for 30 min. Assays 
were performed independently at least three times.
4. Western blot analysis
Preparation of whole cell protein lysates and Western blot analysis were described 
previously. Briefly, cells were then chilled on ice, washed twice with ice-cold PBS, 
and lysed in a buffer (Cell Signaling Technology, Beverly, MA, USA) containing 1 
8mM PMSF and 1X protease inhibitors (Sigma Aldrich). Protein concentrations were 
determined using a Bradford assay kit (Bio-Rad Laboratories). Equal amounts of 
protein in cell lysates were separated by SDS-PAGE, transferred to membranes, 
immunoblotted with specific primary and secondary antibodies, and the blot was
detected by SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher 
Scientific), according to the manufacturer's instructions.
5. Small interfering RNA transfection
The small interfering RNAs (siRNAs) targeting RET or Src were purchased from 
Invitirogen. Cells were plated at a density of 0.5 × 105 per 60 mm dish 1 day before 
transfection. Cells were transfected with 10 nmol/L of siRNAs for 72 hr using 
Lipofectamine (Invitrogen), according to the manufacturer’s instructions. 
Transfected cells were cultured at 37 °C for 48 hr and then treated with or without 
appropriate inhibitors for an additional 24hr prior to lysis. The following sequence:
5’-GGAUUGAAAACAAACUCUAtt-3’ for RET siRNA; 
5’-GCCUCUCAGUGUCUGACUUCGACAA-3’ for Src siRNA; 
5’-CGUUAAUCGCGUAUAAUACGCGUAT-3’ for scramble siRNA. 
Cellular expression of RET and SRC was examined by Western blot analysis. 
6. Human Phospho-Kinase Array
The Human Phospho-Kinase Array Kit (R&D Systems) was used to detect the 
9activation of 49 different protein kinases mediating various aspects of cellular 
proliferation following the manufacturer’s instructions. Briefly, LC-2/ad cells and 
LC-2/ad DR cells were plated in 10-cm dishes and cultured at 37 °C for 28 hr. After 
cell lysis, 500 μg of lysate was applied to a membrane-anchored phosphor kinase 
array and incubated at 4 °C for 24hr. Membranes were exposed to 
chemiluminescent reagents and detected by X-ray film (AGFA).
7. Xenograft studies
All experiments were in accordance with the Yonsei University Medical College 
guidelines and regulations approved by the Association for Assessment and 
Accreditation of Laboratory Animal Care. Six-week-old Nude mice were injected 
subcutaneously with 8.0 x 106 LC-2/ad cells or LCD-2/ad DR cells. Mice were 
randomized to groups of 7 animals to receive either vehicle, vandetanib or dovitinib 
(oral, qd) for the indicated duration of treatment. The length, width, and depth of the 
tumor mass were measured every 2 days using calipers, and tumor volume was 
calculated as: tumor volume = 0.5236 x length x width x depth (mm3). The rate of 
change in body weight (BW) was calculated using the following formula: BW= 
W/W0 x 100, where W and W0 are the body weight on a specific experimental day 
and on the first day of treatment, respectively.
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8. Microarray analysis
Total RNA was extracted using RNeasy columns (Qiagen, Valencia, USA) 
according to the manufacturers’ protocol. RNA purity and integrity were evaluated 
by ND-1000 Spectrophotometer (NanoDrop), Agilent 2100 Bioanalyzer (Agilent 
Technologies). Total RNA was amplified and purified using TargetAmp-Nano 
Labeling Kit forIlluminaExpression BeadChip (EPICENTRE) to yield 
biotinylatedcRNA according to the manufacturer’s instructions. Briefly, 200~500ng
of total RNA was reverse-transcribed to cDNA using a T7 oligo (dT) primer. 
Second-strand cDNA was synthesized, in vitro transcribed, and labeled with biotin-
NTP. After purification, the cRNA was quantified using the ND-1000 
Spectrophotometer. 750 ng of labeled cRNA samples were hybridized to each 
HumanHT-12 v4.0 Expression Beadchipfor 16-18 h at 58°C, according to the 
manufacturer's instructions (Illumina, Inc.). Detection of array signal was carried 
out using Amershamfluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences) 
following the bead array manual. Arrays were scanned with an Illumina bead array 
Reader confocal scanner according to the manufacturer's instructions.
9. Statistical analysis
Data are presented as means ± S.D. of results from three independent 
experiments with similar patterns. Statistical significant values were 
compared using ANOVA and Dunnett’s post-hoc test.
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III. RESULTS
1. Dovitinib inhibits RET kinase activity
Dovitinib, of which chemical structure was shown in Figure 1A, targets type Ⅲ,Ⅳ, 
and Ⅴ RTKs including PDGFRβ, CSF-1R, KIT, FLT3, VEGFR, TrkA, RET and 
FGFRs. To explore RET fusion as an additional target indication of dovitinib, we 
first performed in silico modeling of RET with dovitinib and two other RET-TKIs, 
sunitinib and vandetanib (Fig. 1B). Docking score of RET kinase complex with 
dovitinib, sunitinib and vandetanib were calculated using Glide (Fig. 1B). Docking 
simulation showed almost identical docking structure for dovitinib and two other 
RET-TKIs. Dovitinib-RET complex exhibited high docking score (-9.16), which 
was comparable to those of sunitinib and vandetanib. The structure modeling 
suggested that dovitinib formed hydrogen bonds with A907 and Q905 sites, which 
are located within active site of the RET kinase. According to Novartis 
investigator’s brochure, dovitinib inhibited RET in nanomolar range (7nM) in vitro 
kinase assay. Together, these results strongly suggest that dovitinib has potential to 
inhibit RET kinase activity.
To determine whether dovitinib could inhibit kinase activity of the two most 
common type of fusions, CCDC6-RET and KIF5B-RET, we first transfected 
HEK293 cells with plasmids encoding each fusion variants. Cells were lysed after 
dovitinib treatment and exogenous expression of RET kinase tyrosine 905 (Y905) 
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was determined by immunoblot analysis (Fig. 1C). Dovitinib suppressed the 
phosphorylation of Y905 in both CCDC6-RET and KIF5B-RET fusion kinases, 
resulting in significant reduction of ERK1/2 phosphorylation in CCDC6-RET or 
KIF5B-RET plasmid-transfected HEK293 cells. However, ERK1/2 phosphorylation 
was unaffected by dovitinib in HEK293 cells transfected with mutant KRASG12V
plasmids. Next, we examined whether dovitinib selectively inhibited RET activity, 
leading to decreased ERK1/2 phosphorylation, by transfecting either KRASG12V or 
KIF5B-RET plasmids into HEK293 cells (Fig. 1D). The ERK1/2 phosphorylation 
induced by KRASG12V transfection could not be suppressed by treatment with 
dovitinib, a RET-TKI (vandetanib) or a selective EGFR-TKI (gefitinib). On the 
other hand, dovitinib and vandetanib, but not gefitinib, potently inhibited 
phosphorylation of RET and ERK1/2 in KIF5B-RET transfected HEK293 cells. 
Taken together, these results indicate that dovitinib has ability to specifically 
inhibits RET kinase activity and ERK1/2 signaling mediated by RET.
13
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Figure 1. Inhibition of RET-fusion kinase activity by dovitinib. (A) Chemical 
structure of dovitinib. (B) X-ray structure of dovitinib with RET, sunitinib with 
RET, and vandetanib with RET. (C) Effects of dovitinib on the phosphorylation 
levels of RET in HEK293 cells expressing CCDC6-RET, KIF5B-RET, or KRAS. 
Each transfected HEK293 cells were treated with dmso (-) or dovitinib (DO) for 4hr. 
The expression levels of indicated protein levels were detected by western blot 
analysis using the corresponding antibodies. (D) Western blot analysis showing the 
effect of dovitinib, vandetanib, and gefitnib on expression of indicated proteins. 
Each transfected cells were treated with indicated inhibitor for 4 hr.
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2. Dovitinib induces cell cycle arrest and apoptosis of RET rearranged 
LADC via selective inhibition of RET kinase
LC-2/ad cells were recently reported to harbor the CCDC6-RET rearrangement. we 
evaluated the effect of dovitinib on the growth of the LC-2/ad cells. Compared with 
H1299 cells without RET rearrangement, dovitinib potently suppressed the growth 
of LC-2/ad (IC50 ≒ 0.2μM), further confirming selective anti-tumor effects of 
dovitinib against RET kinase activity (Fig. 2A). Consistent with the results of MTT 
assays, treatment of dovitinib suppressed the phosphorylation of RET and ERK1/2 
in a dose-dependent manner (Fig. 2B). Moreover, dovitinib inhibited the expression 
of cyclin D1 and induced p21 and p27 (Fig. 2B), which was in parallel with the fact 
that dovitinib significantly induced cell cycle arrest at G0/G1 phase (Fig. 2C). 
Furthermore, treatment of dovitinib significantly increased a subpopulation of the 
annexin V-positive apoptotic cells (Fig. 2D). 
As dovitinib is known to target multiple tyrosine kinases, the growth 
suppression effect of dovitinib in LC-2/ad may not be due to selective inhibition of 
RET kinase. To rule out this possibility, introduction of siRET in LC-2/ad 
significantly suppressed the proliferation, whereas siFGFR3, siPDGFR, siFLT3 and 
siKIT had no significant effect on cell viability (Fig. 2E and 2F). 
Taken together, these results suggest that dovitinib induces cell cycle arrest 
and cellular apoptosis via selective inhibition of RET kinase and its downstream 
signaling in lung cancer cells harboring RET rearrangement.
16
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Figure 2. Inhibition of RET-fusion driven tumors by dovitinib. (A) Relative 
survival of H1299 and LC-/2ad against doviitinib after 72 hr treated with dovitinib.
(B) Western blot analysis of CCDC6-RET, ERK1/2, and cyclinD1, p21, p27 and β-
actin in LC-2/ad cells after treated with dovitinib for 4h. (C) LC-2/ad cells were 
treated with dovitinib for 24 or 48 hr. Cell cycle distribution was measured by 
propidium iodide staining and subsequent FACS analysis. Error bars indicate mean 
± SEM (n = 3). **p<0.01, vehicle (DMSO) vs. DO (dovitinib) in both 24 hr and 48 
hr. (D) FACS analysis via Annexin- V/PI double-staining assay was used to observe 
the induction of apoptosis. After treating with dmso or dovitinib for 72 hr, cells 
were stained with annexin V-FITC/PI double staining. Error bars indicate mean ± 
SEM (n=3). *p<0.05, dmso vs. dovitinib. (E) MTT assay of siCON, siFGFR3, 
siPDGFRb, siFLT3, siKIT, or siRET-transfected LC-2/ad cells. Indicated siRNA-
transfected LC-2/ad cells were incubated for 72 hr before treating with MTT 
solution. (F) Colony formation assay of siCON, siFGFR3, siPDGFRb, siFLT3, 
siKIT, or siRET-transfected LC-2/ad cells. . Indicated siRNA-transfected LC-2/ad 
cells were incubated for 14 days before staining with crystal violet.
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3. Dovitnib inhibits growth of RET rearranged LADC more effectively than 
other RET-TKIs
We next compared antitumor effects of dovitinib with other known RET-TKIs, such 
as vandetanib, sunitinib and sorafenib, using gefitinib, a selective EGFR-TKI, as a 
negative control. Contrary to gefitinib, dovitinib suppressed the phosphorylation of 
RET and ERK1/2 and the expression of cyclin D1 as potently as other known RET-
TKIs (Fig. 3A). Notably, compared with other RET-TKIs, dovitinib exerted the 
most potent inhibitory effects on the proliferation of LC-2/ad cells in MTT assays 
(Fig. 3B). The superior antitumor activity of dovitinib to vandetanib, sunitinib and 
sorafenib in LC-2/ad cells became more evident through long-term (14 days) colony 
formation assays (Fig. 3C). Taken together, our data suggest that dovitinib inhibits 
growth of RET rearranged LADC at least as effectively as other known RET-TKIs.
19
20
Figure 3. Differences in the cell growth inhibition efficacy of RET-fusion 
driven NSCLC between dovitinib and other RET inhibitors. (A) Western blot 
analysis of indicated markers in LC-2/ad cells after treated with dovitinib, gefitinib, 
vandetanib, sunitinib, or sorafenib for 4hr. (B) MTT assays of LC-2/ad. Cells were 
treated with 1M of sorafenib, sunitinib, vandetanib, or dovitinib for 72 hr, and cell 
viability was determined using MTT (5ug/ml) solution by measuring the absorbance 
at 540nm in a microplate reader. Means are drived from five replicate (n=3). Error 
bars indicate mean ± SE of three replicates. *P < 0.05, vandetanib versus dovitinib; 
**P < 0.01, ***P < 0.001, dovitinib versus sunitinib or sorafenib in LC-2/ad cells, 
respectively. (C) Colony formation assay of LC-2/ad cells. Cells were grown in the 
absence or presence of the indicated inhibitor for 14 days. All cells were fixed and 
stained with crystal violet (0.005%), represent quantification.
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4. Anti-tumor activity of dovitinib in LC-2/ad xenograft models
To evaluate anti-tumor activity of dovitinib in vivo, we tested the effects of 
dovitinib and vandetanib on the growth of LC-2/ad xenograft tumors established in 
nude mice. Mice treated with dovitinib showed remarkable tumor regression at all 
doses without significant weight loss at 30 mg/kg and 60 mg/kg doses of dovitinib 
(Fig. 4A). In waterfall plots, the percent volume changes of the individual tumors 
were greater in dovitinib treatment group compared with those in vandetanib group, 
showing complete tumor regression (-100%) in 3 out of 7 mice treated with two 
different doses of dovitinib (Fig. 4B). Dovitinib suppressed phosphorylation of RET
and ERK1/2 in a dose dependent manner relative to vehicle treatment, as assessed 
by immunoblots and immunohistochemistry of tumor tissues from xenograft (Fig. 
4C and 4D). Taken together, our in vitro and in vivo findings confirm that dovitinib 
is effective against RET fusion-positive LADC.
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Figure 4. Anti-tumor activity of dovitinib against RET-fusion driven tumors. 
(A) Mice bearing LC-2/ad cells were treated with vehicle only (Vehicle), dovitinib 
(DO 30 mg/kg), dovitinib (DO 60 mg/kg), or vandetanib (VA 50 mg/kg) for 32days. 
Average percent change in tumor volume relative to initial tumor volume is shown. 
Error bars represent SEM. ***P < 0.0001 for vehicle vs. dovitinib 30mg/kg 
treatment group. (B) Waterfall plots showing the percent change in volume (relative 
to initial tumor volume) for the individual tumors in each treatment group. 
Maximum regression tumors for each group are indicated. (C) Mice bearing LC-
2/ad cells expressing CCDC6-RET were orally administered a dose of 0(vehicle), 
30 mg/kg, 60 mg/kg dovitinib (DO), or 50 mg/kg vandetanib (VA) and the tumors 
were collected and lysed at 6hours postdosing. The expression levels of phospho-
RET, RET, phospho-ERK, ERK, and b-actin were detected by immunoblot analysis 
using the appropriate antibodies. (D) Immunohistochemical (IHC) analysis of LC-
2/ad xenograft tumor samples. Mice were orally administered a dose of 0(vehicle), 
or 60 (dovitinib 60 mg/kg) for 6 hr and sacrificed, and tumors were stained with 
indicated antibodies. Photos shown are representative fields in each group in low 
and high magnification. Scale bars in the main images and in the insets indicate 100 
and 50 mM, respectively.
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5. Src activation in acquired dovitinib-resistant cells
In most targeted agents, acquired resistance eventually develops after an initial 
response.20 To identify potential mechanisms of acquired resistance to dovitinib, we 
established LC-2/ad DR cells with acquired resistance to dovitinib by exposing LC-
2/ad cells to increasing doses of dovitinib. LC-2/ad DR cells showed strong 
resistance to dovitinib (IC50> 3 μmol/L; Fig. 5A). Next, LC-2/ad and LC-2/ad DR 
cells were subjected to genome-wide gene expression profiling using cDNA 
microarray. Gene-set enrichment analysis against Kyoto Encyclopedia of Genes and 
Genomes (KEGG) database showed that focal adhesion pathway was significantly 
enriched, with Src contributing significantly to the core enrichment, in LC-2/ad DR 
cells, as compared with LC-2/ad cells (Fig. 5B). LC-2/ad DR cells displayed higher 
phosphorylation level of Src and focal adhesion kinase (FAK) in phospho-kinase 
array than LC-2/ad cells, which was confirmed by immunoblots (Fig. 5C and 5D). 
Increased Src activation in LC-2/ad DR cells led to constitutive ERK1/2 
phosphorylation unresponsive to dovitinib treatment (Fig. 5D). Interestingly, 
contrary to LC-2/ad cells, LC-2/ad DR cells did not activate RET kinase any more, 
suggesting the loss of addiction to RET fusion in these cells (Fig. 5D).
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Figure 5. Src hyperactivation in acquired dovitinib-resistant cells. (A) MTT 
assay comparing cell proliferation of indicated parental LC-2/ad cells and their 
corresponding acquired dovitinib-resistant LC-2/ad DR cells upon treatment with 
dovitnib for 72 hr. (B) The GSEA demonstrating a significant enrichment of the set 
of focal adhesion pathway genes among significantly differentially expressed genes 
between LC-2/ad and LC-2/ad DR cells. (C) The phosphorylation state was detected 
by R&D Systems Proteome Profiler Phospho-Kinase Array in LC-2/ad or LC-2/ad 
DR. Key activated kinase are indicated (FAK and Src). (D) Lysates from LC-2/ad 
and LC-2/ad DR cells were evaluated by western blotting to determine total and 
phosphorylated protein levels from the arrays in (C).
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6. Src inhibition overcomes dovitinib resistance in vitro
Previous studies have demonstrated that Src sits on the signaling node mediating 
resistance to multiple anticancer agents.21, 22 The increased activation of Src led us 
to hypothesize that Src activation directly mediated acquired resistance to dovitinib 
in LC-2/ad DR cells. To test this hypothesis, we inhibited Src activity using either 
saracatinib, a selective Src inhibitor, or siRNA targeting Src (siSrc) in LC-2/ad DR 
cells. Although dovitinib and other known RET-TKIs could not inhibit tumor 
growth in colony formation assays, saracatinib significantly exerted growth 
inhibitory effects on LC-2/ad DR cells (Fig. 6A). Furthermore, siSrc could 
efficiently inhibit tumor growth only in LC-2/ad DR cells (Fig. 6B). On the other 
hand, siRET could not inhibit tumor growth in LC-2/ad DR cells, suggesting the 
minimal role of RET signaling in survival of these cells (Fig. 6B). Consistent with 
cell viability data, inhibition of RET kinase by dovitinib or siRET abrogated 
ERK1/2 activity only in RET-dependent LC-2/ad cells, and inhibition of Src by 
saracatinib or siSrc abrogated ERK1/2 activity only in Src-dependent LC-2/ad DR 
cells (Fig. 6C and 6D). Finally, concurrent inhibition of RET and Src signaling did 
not show synergistic antitumor effect in LC-2/ad DR cells, further supporting 
complete loss of dependence on RET signaling for survival upon acquisition of 
acquired resistance to dovitinib (Fig. 6E). 
Given the activation of FAK and mRNA upregulation of integrin, we 
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hypothesized that FAK-integrin axis was involved in the Src activation. To rule out 
this hypothesis, we used PF-562,271, ATP-competitive reversible inhibitor of FAK. 
Unexpectedly, PF-562,271 had neither anti-proliferation effect nor inhibition of 
downstream ERK1/2 activation in LC-2/ad DR cells (data not shown). Expressions 
of integrins in LC-2/ad DR cells were similar with LC-2/ad cells (data not shown).
Taken together, these data indicate an essential role of Src in mediating the
acquired resistance to dovitinib in RET fusion-positive LADC.
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Figure 6. Loss of dependency on RET-fusion and gain of dependency on Src in 
dovitinib-resistant cells. (A) Colony formation assay of LC-2/ad DR cells. Cells 
were grown in the absence or presence of the indicated inhibitor for 14 days. All 
cells were fixed, stained with crystal violet (0.005%). (B) Colony formation assay 
of LC-2/ad and LC-2/ad DR cells. Cells were transfected with indicated siRNA and 
grown for 14 days. All cells were fixed, stained with crystal violet (0.005%). (C) 
Western blot analysis assessing the effect of dovitinib, saracatinib, or combination 
treatment on LC-2/ad and LC-2/ad DR cells. Cells were treated indicated inhibitor(s) 
for 4 hr. Lysates were evaluated by western blotting with the indicated antibodies.
(D) Western blot analysis of assessing the dependency, whether cell survival is 
mediated by CCDC6-RET or Src. Cells were transfected with siCON, siRET, or 
siSrc for 72 hr. Lysates were evaluated by western blotting with the indicated 
antibodies. (E) MTT assay of single or combination treatment of dovitinib and 
saracatinib in LC-2/ad and LC-2/ad DR cells.  LC-2/ad and LC-2/ad DR cells were 
incubated for 72h with indicated inhibitors before treating with MTT solution. Error 
bars indicate mean ± SE of three replicates. ***P < 0.001, dovitinib or saracatinib 
treated LC-2/ad versus LC-2/ad DR; ns, saracatinib treated LC-2/ad DR versus 
combination treated LC-2/ad DR.
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IV. DISCUSSION
In our study, we evaluated and compared antitumor activity of dovitinib in RET
fusion-driven LADC models. Dovitinib efficiently suppressed growth of RET-
rearranged LADC in vitro and in vivo by inhibiting autophosphorylation of RET and 
was shown to be at least as efficacious as other known RET-TKIs, such as sorafenib, 
sunitinib and vandetanib. Our data provided the preclinical evidence supporting a 
rationale for the clinical development of dovitinib in patients with RET fusion-
driven LADC. Furthermore, we found that increased activation of Src mediated 
acquired resistance to dovitinib by phosphorylating RET downstream effector 
ERK1/2 in RET fusion-positive LADC. 
Given that RET rearrangement is a druggable target in LADC, a number of
clinical trials have been designed to investigate the therapeutic effects of 
multikinase inhibitors targeting RET, such as vandetanib (trial registration ID: 
NCT01823068), sunitinib (NCT01829217), cabozantinib (NCT01639508) and 
lenvatinib (NCT01877083), in RET fusion-positive LADC. In a recent report of 
preliminary efficacy in patients with RET fusion-positive LADC, cabozantinib, an 
inhibitor of MET, vascular endothelial growth factor receptor (VEGFR) and RET, 
achieved partial responses in 2 patients and durable stable disease in 1 patient.12
Vandetanib, an inhibitor of VEGFR, EGFR and RET, showed a dramatic response 
in a patients with advanced RET fusion-positive LADC.16 Moreover, alectinib 
(CH5424802), which has been known to be a selective inhibitor of ALK, showed 
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antitumor activity against RET fusion-driven LADC models by inhibiting oncogenic 
RET fusion signaling.23 Our data support the inclusion of dovitinib in the 
therapeutic armamentarium of targeted agents currently being tested for RET
fusion-positive LADC. 
Targeted agents that exploit genetic vulnerabilities in human cancers have 
now been clinically validated as effective cancer therapies. However, clinical 
efficacy of these agents is limited by the rapid emergence of drug resistance, which 
remains a substantial challenge to the clinical management of advanced cancers.20, 
24-27To our knowledge, this is the first report on the mechanism of acquired 
resistance to the RET inhibitor describing a link between Src-dependent survival 
signal activation and drug resistance in RET fusion-positive LADC. 
Src regulates many fundamental cellular processes, including cell growth, 
differentiation, migration and drug resistance.21, 22, 28, 29 In our study, acquisition of 
acquired resistance to dovitinib is attributable to the activation of a Src-driven 
bypass signaling pathway. We observed marked activation and expression of Src in 
LC-2/ad DR cells, as compared with the LC-2/ad cells. The blockade of Src 
signaling by saracatinib or siSrc resulted in the marked suppression of ERK1/2 
phosphorylation, suggesting a dominant role of Src on ERK1/2 activation in LC-
2/ad DR cells. Consistent with these results, treatment with saracatinib and siSrc 
dramatically suppressed cell growth in LC-2/ad DR cells. The disappointing lack of 
synergy in the combined treatment of dovitinib and saracatinib may be due to the 
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fact that survival of LC-2/ad DR cells no longer depend on the activity of RET
fusion kinase (Fig. 5D and 6E). Similar to our findings, loss of addiction to mutant 
EGFR resulted in gain of addiction to both HER2/HER3 and PI3K/Akt signaling to 
acquire EGFR-TKI resistance.30
Integrins are a family of adhesion receptors for extracellular matrix (ECM) 
proteins, integrins can transduce biochemical signals into the cell to regulate a 
variety of cellular functions, including proliferation, migration, survival and drug 
resistance.31-34 Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase which 
mediates integrin signaling pathways. Src family of cytosolic protein tyrosine 
kinases function intimately with FAK in integrin signaling pathways.35, 36 In our 
study, focal adhesion kinase (FAK) activity was increased in LC-2/ad DR cells (Fig. 
5D). These data also raise the question as to whether FAK could play an important 
role in the enhanced Src activation, resulting in the acquisition of dovitinib 
resistance in LC-2/ad DR cells. However, the inhibition of FAK activity using PF-
562,271 could not suppress the downstream ERK1/2 activation and LC-2/ad DR 
cell growth (data not shown). Protein levels of integrins in LC-2/ad DR cells were 
similar with LC-2/ad cells and treatment of intergrin b1 could not inhibit the cell 
growth in LC-2/ad DR cells (data not shown). These data suggest that integrin-
mediated FAK activation may not be critically involved in acquired resistance to 
dovitinib in LC-2/ad DR cell. Instead, Src, as a common node downstream of 
multiple drug resistance pathways, might be activated by various signal inputs from 
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specific RTKs, nonreceptor tyrosine kinases or loss of protein tyrosine phosphatase 
activity.21, 29 Therefore, it remains to be further studied what mediates the enhanced 
activity of Src.
V. CONCLUSION
In conclusion, these findings warrant further evaluation of clinical development of 
dovitinib in RET rearrangement patients and targeting Src signaling is effective in 
RET rearranged LADC with acquired resistance to dovitinib.
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ABSTRACT (IN KOREAN)
Dovitinib (TKI258)의 RET fusion 비소세포폐암의 항 종양 활성과 획득
내성기전
<지도교수 조 병 철>
연세대학교 대학원 의과학과
강 찬 우
RET fusion은 폐선암에서 새롭게 발견된 driver gene이다. Dovitinib은
FGFR, VEGFR, 그리고 PDGFR에 대한 키나아제 저해제로 RET fusion 
폐선암에 대한 항 종양 활성에 대해서는 아직 밝혀진 바가 없다. 본
연구의 목적은 RET fusion 폐선암에 대한 dovitinib의 항 종양 활성과
획득 내성기전을 밝히는데 있다. 인실리코 분석결과 dovitinib은 RET 
kinase domain 부분에 강하게 결합하는 것을 확인하였고, CCDC6-RET 
fusion을 갖는 폐선암 세포주인 LC-2/ad의 RET과 ERK의 인산화를
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억제하는 동시에 세포주기의 G1기에 억류시켰다. 이러한 dovitinib의
치료적 효과는 RET을 siRNA를 이용한 저해효과와 같은 결과를 보였다. 
또한 CCDC6-RET이나 KIF5B-RET을 발현하는 HEK293 세포주에
dovitinib을 처리했을 때 선택적으로 RET 키나아제의 활성을 선택적으로
억제하는 것을 확인할 수 있었다. 종양 이종이식 (tumor xenograft)을
통해서 dovitinib이 RET fusion을 발현하는 종양의 성장을 억제하였고
이것은 인비트로에서 확인한 결과를 뒷받침하는 것을 알 수 있었다. 더
나아가 이 연구에서는 RET fusion 폐선암에서 dovitinib의 내성기전을
밝히기 위해 dovitinib 획득 저항 세포주 (LC-2/ad DR)을 구축하였고, 이
세포주는 RET siRNA에 의해서 ERK의 인산화와 세포성장이 억제되지
않았다. Micro array 분석을 통해 Src의 인산화와 발현이 dovitinib 저항
세포주에서 높게 확인되었고 Src 키나아제 저해제인 saracatinib을
처리하였을 때 ERK의 인산화와 세포성장이 감소하는 것을 확인하였다. 
따라서 이번 연구는 dovitinib이 RET fusion 폐선암에 대한 치료방법이 될
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수 있다는 가능성과 dovitinib에 대한 획득 내성은 Src을 표적하여 극복할
수 있음을 시사한다.
핵심되는 말: 폐 선암, 비소세포폐암, RET rearrangement, dovitinib (TKI258), 
Src, 획득 저항성
